632 related articles for article (PubMed ID: 18329459)
1. Bleeding in cardiac surgery: the use of aprotinin does not affect survival.
Pagano D; Howell NJ; Freemantle N; Cunningham D; Bonser RS; Graham TR; Mascaro J; Rooney SJ; Wilson IC; Cramb R; Keogh BE
J Thorac Cardiovasc Surg; 2008 Mar; 135(3):495-502. PubMed ID: 18329459
[TBL] [Abstract][Full Text] [Related]
2. Effects of aprotinin on short-term and long-term outcomes after coronary artery bypass grafting surgery.
Wang X; Zheng Z; Ao H; Zhang S; Wang Y; Zhang H; Hu S
Ann Thorac Surg; 2010 May; 89(5):1489-95. PubMed ID: 20417766
[TBL] [Abstract][Full Text] [Related]
3. Aprotinin in cardiac surgery patients: is the risk worth the benefit?
Stamou SC; Reames MK; Skipper E; Stiegel RM; Nussbaum M; Geller R; Robicsek F; Lobdell KW
Eur J Cardiothorac Surg; 2009 Nov; 36(5):869-75. PubMed ID: 19782574
[TBL] [Abstract][Full Text] [Related]
4. Aprotinin in primary cardiac surgery: operative outcome of propensity score-matched study.
Ngaage DL; Cale AR; Cowen ME; Griffin S; Guvendik L
Ann Thorac Surg; 2008 Oct; 86(4):1195-202. PubMed ID: 18805159
[TBL] [Abstract][Full Text] [Related]
5. Aprotinin and cardiac surgery.
DeAnda A
J Thorac Cardiovasc Surg; 2008 Mar; 135(3):492-4. PubMed ID: 18329458
[No Abstract] [Full Text] [Related]
6. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery.
Karkouti K; Wijeysundera DN; Yau TM; McCluskey SA; Tait G; Beattie WS
Anesth Analg; 2010 Jan; 110(1):21-9. PubMed ID: 19910626
[TBL] [Abstract][Full Text] [Related]
7. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
Dietrich W; Spannagl M; Boehm J; Hauner K; Braun S; Schuster T; Busley R
Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201
[TBL] [Abstract][Full Text] [Related]
8. Aprotinin and the risk of death and renal dysfunction in patients undergoing cardiac surgery: a meta-analysis of epidemiologic studies.
Gagne JJ; Griesdale DE; Schneeweiss S
Pharmacoepidemiol Drug Saf; 2009 Apr; 18(4):259-68. PubMed ID: 19185048
[TBL] [Abstract][Full Text] [Related]
9. Coronary artery bypass grafting after aprotinin: are we doing better?
Beckerman Z; Shopen Y; Alon H; Cohen O; Nir RR; Adler Z; Bolotin G
J Thorac Cardiovasc Surg; 2013 Jan; 145(1):243-8. PubMed ID: 23072702
[TBL] [Abstract][Full Text] [Related]
10. Aprotinin is not associated with postoperative renal impairment after primary coronary surgery.
Lindvall G; Sartipy U; Ivert T; van der Linden J
Ann Thorac Surg; 2008 Jul; 86(1):13-9. PubMed ID: 18573391
[TBL] [Abstract][Full Text] [Related]
11. A comparison before and after aprotinin was suspended in cardiac surgery: different results in the real world from a single cardiac center in China.
Wang X; Zheng Z; Ao H; Zhang S; Wang Y; Zhang H; Li L; Hu S
J Thorac Cardiovasc Surg; 2009 Oct; 138(4):897-903. PubMed ID: 19660368
[TBL] [Abstract][Full Text] [Related]
12. Is cardiac surgery safe in extremely obese patients (body mass index 50 or greater)?
Sun X; Hill PC; Bafi AS; Garcia JM; Haile E; Corso PJ; Boyce SW
Ann Thorac Surg; 2009 Feb; 87(2):540-6. PubMed ID: 19161775
[TBL] [Abstract][Full Text] [Related]
13. Tranexamic acid and aprotinin in low- and intermediate-risk cardiac surgery: a non-sponsored, double-blind, randomised, placebo-controlled trial.
Later AF; Maas JJ; Engbers FH; Versteegh MI; Bruggemans EF; Dion RA; Klautz RJ
Eur J Cardiothorac Surg; 2009 Aug; 36(2):322-9. PubMed ID: 19250838
[TBL] [Abstract][Full Text] [Related]
14. Putting the record straight on aprotinin as safe and effective: results from a mixed treatment meta-analysis of trials of aprotinin.
Howell N; Senanayake E; Freemantle N; Pagano D
J Thorac Cardiovasc Surg; 2013 Jan; 145(1):234-40. PubMed ID: 22889481
[TBL] [Abstract][Full Text] [Related]
15. Retrospective cohort analysis of a single dose of aprotinin use in children undergoing cardiac surgery: a single-center experience.
Fan Y; Lin R; Yang L; Ye L; Yu J; Shu Q
Paediatr Anaesth; 2013 Mar; 23(3):242-9. PubMed ID: 23189963
[TBL] [Abstract][Full Text] [Related]
16. Aprotinin and renal dysfunction after pediatric cardiac surgery.
Székely A; Sápi E; Breuer T; Kertai MD; Bodor G; Vargha P; Szatmári A
Paediatr Anaesth; 2008 Feb; 18(2):151-9. PubMed ID: 18184247
[TBL] [Abstract][Full Text] [Related]
17. Effects of aprotinin dosage on renal function: an analysis of 8,548 cardiac surgical patients treated with different dosages of aprotinin.
Dietrich W; Busley R; Boulesteix AL
Anesthesiology; 2008 Feb; 108(2):189-98. PubMed ID: 18212563
[TBL] [Abstract][Full Text] [Related]
18. Use of aprotinin in cardiac surgery: effectiveness and safety in a population-based study.
Jakobsen CJ; Søndergaard F; Hjortdal VE; Johnsen SP
Eur J Cardiothorac Surg; 2009 Nov; 36(5):863-8. PubMed ID: 19782573
[TBL] [Abstract][Full Text] [Related]
19. Early and late outcomes of cardiac surgery in octogenarians.
Zingone B; Gatti G; Rauber E; Tiziani P; Dreas L; Pappalardo A; Benussi B; Spina A
Ann Thorac Surg; 2009 Jan; 87(1):71-8. PubMed ID: 19101271
[TBL] [Abstract][Full Text] [Related]
20. Aprotinin reduces bleeding and blood product use in patients treated with clopidogrel before coronary artery bypass grafting.
Lindvall G; Sartipy U; van der Linden J
Ann Thorac Surg; 2005 Sep; 80(3):922-7. PubMed ID: 16122456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
